Anapole Technologies

RGFields™ technology

Resonance Generating Fields:

A Revolution in Capability

Resonance Generating Fields (RGFIELDS) technology uses broadband electromagnetic resonance to detect frequencies that are specific to certain diseases or substances, detecting the presence of a particular illness or substance. The technology can also transmit an amplified electromagnetic field which is “tuned” to the resonant frequencies of a selected patient or substance.

Pre-clinical studies and clinical trials have demonstrated the effectiveness of the treatment against HIV, tuberculosis, and glioblastoma multiforme.

When a patient or substance is exposed to an appropriately-tuned electromagnetic field, electromagnetic resonance is induced within the target which significantly affects the proliferation and viability of that disease. These same resonances can be used to rapidly detect the presence of said disease or substance.

A Paradigm Shift

  • RGFIELDS is patented for diagnostics and therapeutics
  • We develop new therapies in months rather than years
  • Noninvasive – Nothing attached or inserted – No known toxicity
  • Penetrates the blood-brain barrier
  • Self -tuning
  • Capability for group treatment
  • Targets multiple disease progression points simultaneously
  • Scans for multiple diseases concurrently
  • Lower cost compared with other treatment modalities

RGFIELDS: How It Works

1.  SMEs identify specific disease progressor “targets”.

2.  RGFIELDS captures, amplifies and transmits resonant frequencies of the targets to form a “tuned” electromagnetic field.

3.  When a patient is exposed to the tuned electromagnetic field, resonance is induced within the targets. 

4.  This resonance knocks down disease viability and its ability to spread.

These same resonances can be used to rapidly detect the presence of the disease.

Penetration Depth

The aqua shaded area on the chart shows the frequency range of our 6th generation equipment. Since we broadcast amplified and modulated resonant frequencies from 100 MHz to 6 GHz; penetration in all parts of the body is substantial.

The penetration depth is always calculated based on the point where signal strength is reduced to ≈ 37% of outside power. One can see why we stopped transmission at 6 GHz because of the fall off in penetration.

Unlike drugs, non-ionizing radiation from our resonance generating fields device easily penetrates the blood-brain barrier, providing efficient therapy with no known toxic side effects.

RGFields device trial


Extensive studies have been conducted using previous generations of RGF devices.

Anapole continues to pursue additional testing opportunities and third-party verification of our results.

Our First Priority:  Glioblastoma

Cell studies on glioblastoma multiforme cancer (U-87 MG strain) were conducted at the University at Albany Cancer Research Center in Rensselaer, NY.

The highlight was a 40% decrease in viable cancer cells.

What is Glioblastoma?

Glioblastoma is an aggressive form of cancer found in the brain.

  • It is one of the most complex, deadly, and treatment-resistant cancers
  • More than 10,000 individuals in the United States will succumb to glioblastoma every year
  • The five-year survival rate for glioblastoma patients is only 6.8 percent, and the average length of survival for glioblastoma patients is estimated to be only 8 months
  • Survival rates and mortality statistics for GBM have been virtually unchanged for decades
  • Despite first being identified in the scientific literature in the 1920’s, there have only been five drugs and one device ever approved by the FDA for the treatment of glioblastoma
  • None of these treatments have succeeded in significantly extending patient lives beyond a few extra months

Why Target Glioblastoma

  • When compared with unexposed control group, RGFIELDS induced a 40% reduction in viable glioblastoma cancer cells
  • Cells exposed to RGFIELDS showed DNA fragmentation approximately 8 times higher than those of the unexposed control group
  • RGFIELDS penetrates the blood-brain barrier and can be used pre- or post-surgery or as an adjuvant to increase the effectiveness of the body’s immune response
  • There are no known toxic side effects with RGFIELDS treatment – multiple sessions are possible both before and after surgery


Phase 1 and Phase 2 clinical trials with participating HIV-positive patients were conducted at the Nelson Mandela School of Medicine in Durban, South Africa. These studies targeted HIV’s ENV and GAG proteins. Highlights:

  • Treatment is safe.
  • Dose response is confirmed.
  • Benefit in terms of time-to-death and time-to-uptake of antiretroviral treatment.
  • Significant and lasting decrease in apoptosis of lymphocytes.
  • Significant and lasting increase in viable lymphocytes.

Additional information regarding cell, animal, and human studies are available upon request.

Continue the Conversation

Our team is excited to build towards the mission and vision of Anapole Technologies .

If these endeavors resonate with you, contact us today.

Copyright © 2024 Anapole Technologies Inc.